PL373655A1 - Preparat z dużą dawką ibandronianu - Google Patents

Preparat z dużą dawką ibandronianu

Info

Publication number
PL373655A1
PL373655A1 PL03373655A PL37365503A PL373655A1 PL 373655 A1 PL373655 A1 PL 373655A1 PL 03373655 A PL03373655 A PL 03373655A PL 37365503 A PL37365503 A PL 37365503A PL 373655 A1 PL373655 A1 PL 373655A1
Authority
PL
Poland
Prior art keywords
high dose
formulation
ibandronate formulation
dose ibandronate
ibandronate
Prior art date
Application number
PL03373655A
Other languages
English (en)
Other versions
PL212072B1 (pl
Inventor
Hans-G. Kaestle
Bernard Meyer
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32524013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL373655(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL373655A1 publication Critical patent/PL373655A1/pl
Publication of PL212072B1 publication Critical patent/PL212072B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
PL373655A 2002-12-20 2003-08-07 Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania PL212072B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02028745 2002-12-20

Publications (2)

Publication Number Publication Date
PL373655A1 true PL373655A1 (pl) 2005-09-05
PL212072B1 PL212072B1 (pl) 2012-08-31

Family

ID=32524013

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373655A PL212072B1 (pl) 2002-12-20 2003-08-07 Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania

Country Status (36)

Country Link
US (1) US7923028B2 (pl)
EP (2) EP1596870B2 (pl)
JP (1) JP4427453B2 (pl)
KR (1) KR100694550B1 (pl)
CN (1) CN1649598B (pl)
AR (2) AR037560A1 (pl)
AT (1) ATE369139T1 (pl)
AU (1) AU2003250218B2 (pl)
BR (1) BR0309691A (pl)
CA (1) CA2484494C (pl)
CR (1) CR7549A (pl)
CY (2) CY1107757T1 (pl)
DE (1) DE60315514T3 (pl)
DK (2) DK1790347T3 (pl)
EC (1) ECSP045418A (pl)
EG (1) EG26027A (pl)
ES (2) ES2530791T3 (pl)
HK (1) HK1080714A1 (pl)
HR (1) HRP20041013B1 (pl)
IL (2) IL164956A (pl)
JO (1) JO2663B1 (pl)
MX (1) MXPA04010866A (pl)
MY (1) MY143550A (pl)
NO (1) NO329690B1 (pl)
NZ (2) NZ555514A (pl)
PA (1) PA8580601A1 (pl)
PE (1) PE20040416A1 (pl)
PL (1) PL212072B1 (pl)
PT (2) PT1790347E (pl)
RU (1) RU2315603C2 (pl)
SG (1) SG174628A1 (pl)
SI (2) SI1596870T2 (pl)
TW (1) TWI342215B (pl)
UY (1) UY27942A1 (pl)
WO (1) WO2004056373A1 (pl)
ZA (1) ZA200408822B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095029A1 (en) 2002-05-10 2003-11-20 F. Hoffmann-La Roche Ag Bisphosphonic acid for the treatment and prevention of osteoporosis
EP1680092A2 (en) * 2003-09-29 2006-07-19 Cipla Ltd. Pharmaceutical formulation with improved stability
DE602005025977D1 (de) * 2004-08-23 2011-03-03 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
HUE042316T2 (hu) * 2005-02-01 2019-06-28 Atnahs Pharma Uk Ltd Az Ibandronát A polimorf orvosi alkalmazása
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
DE102006012866B4 (de) 2006-03-19 2009-04-09 Uic Gmbh Verfahren zur Abtrennung leichtflüchtiger Komponenten aus einem Stoffgemisch sowie Vorrichtung zur Durchführung dieses Verfahrens
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
WO2008026907A1 (es) * 2006-08-29 2008-03-06 Espinosa Abdala Leopoldo De Je Composición farmacéutica que comprende ibandronato y vitamina d3 para el tratamiento de osteoporosis
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
WO2009018834A1 (en) * 2007-08-06 2009-02-12 Pharmathen S.A. Pharmaceutical composition containing bisphosphonate and method for the preparation thereof
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102000094B (zh) * 2010-09-27 2013-03-27 天津南开允公医药科技有限公司 一种含有伊班膦酸的药物组合物及制备工艺
KR101244414B1 (ko) * 2010-11-05 2013-03-18 주식회사 바이오파마티스 고함량 이반드론산 함유 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2012093974A1 (en) 2011-01-06 2012-07-12 Mahmut Bilgic Improved bisphosphonate formulations
US9854831B2 (en) 2012-01-20 2018-01-02 Altria Client Services Llc Oral product
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US139378A (en) * 1873-05-27 Improvement in folding-guides for sewing-machines
US195171A (en) * 1877-09-11 Improvement in jacks for vehicles
US175884A (en) * 1876-04-11 Improvement in galvanic batteries
US147484A (en) * 1874-02-17 Improvement in shirt-bosom supporters
US118634A (en) * 1871-08-29 Improvement in attachments of band-cutters and thrashing-machines
US87550A (en) * 1869-03-09 Improvement in direct-acting steam-engines
US97469A (en) * 1869-11-30 Improved compound for disinfecting- and deodorizing
DE1248654B (de) 1964-11-11 1967-08-31 Albright & Wilson (Mf g) Limited, Oldbury, Warwickshire (Großbritannien) Verfahren zur Herstellung von Phosphonsäuren und deren Salzen
DE1251759B (de) 1965-03-30 1967-10-12 The Procter S. Gamble Company, Cincinnati, Ohio (V St A) Verfahren zur kontinuierlichen Herstellung von Athan 1 hydroxy - 1 1-diphosphonsaure
US3475486A (en) 1966-09-12 1969-10-28 Monsanto Co Process for preparing phosphonic acids
US4134969A (en) 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4073838A (en) 1974-08-12 1978-02-14 Boehringer Ingelheim Gmbh Granulating process
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
BE885139A (fr) 1981-03-09 1981-03-09 Vs Chemicko Technologicka Prah Acide 6-amino-1-hydroxyhexylidene-disphosphonique, sels de cet acide et procede de fabrication de ces produits
CH658009A5 (de) 1982-02-12 1986-10-15 Concast Service Union Ag Verfahren und plattenkokille zum kuehlen und stuetzen eines stranges in einer plattenkokille einer stahlstranggiessanlage.
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IT1195993B (it) 1984-01-12 1988-11-03 Gentili Ist Spa Forme farmaceutiche a base di difosfonati
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
DE3512536A1 (de) 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3776880D1 (de) 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
GB8808138D0 (en) 1988-04-07 1988-05-11 Leo Pharm Prod Ltd Chemical compounds
FR2629716B1 (fr) 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4958839A (en) 1988-07-12 1990-09-25 Guzik Technical Enterprises, Inc. Disc clamp employing resilient cone for spreading balls
US4990503A (en) 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives
US5018651A (en) 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5356887A (en) 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5203253A (en) * 1990-10-09 1993-04-20 Ore-Ida Foods, Inc. Automatic air cooking system for vending machines
US5262173A (en) 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
TW237386B (pl) 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) † 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
DE69530308T2 (de) 1994-09-22 2003-10-16 Akzo Nobel Nv Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
FR2727629A1 (fr) 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
US20010051616A1 (en) 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
US6123964A (en) * 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
JPH11513989A (ja) † 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
CN1222079A (zh) * 1996-04-20 1999-07-07 曼海姆泊灵格股份公司 含有伊波膦酸盐的口服药物制剂
US6905701B2 (en) 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
RU2193880C2 (ru) 1997-06-11 2002-12-10 Дзе Проктер Энд Гэмбл Компани Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
IL121623A (en) 1997-08-26 2000-06-29 Unipharm Ltd Process for the preparation of solid oral dosage forms comprising alendronic acid
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
CA2336201A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
IT1303672B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) † 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
DE19846687C2 (de) 1998-10-09 2001-07-26 Auer Dorothee Chirurgische Hilfsvorrichtung zur Verwendung beim Ausführen von medizinischen Eingriffen und Verfahren zum Erzeugen eines Bildes im Rahmen von medizinischen Eingriffen
TR200101546T2 (tr) 1998-12-04 2001-11-21 Roche Diagnostics Gmbh İç-protezlerde kemik entegrasyonunu iyileştirmek üzere ibandronat kullanılması.
SE9901272D0 (sv) 1999-04-09 1999-04-09 Astra Ab New improved formulation
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
AU2001251391A1 (en) 2000-04-06 2001-10-23 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
CN1450913A (zh) † 2000-07-06 2003-10-22 惠氏公司 二膦酸酯、雌激素药物以及任选雌激素的联合应用
CA2415643C (en) * 2000-07-17 2010-11-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption
US6638920B2 (en) 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
MXPA03006565A (es) 2001-01-23 2005-07-29 Gador Sa Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.
AR034199A1 (es) 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
AU2002221339B2 (en) 2001-02-06 2006-04-27 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
NZ527157A (en) 2001-03-01 2005-04-29 Emisphere Tech Inc Compositions for delivering bisphosphonates
US6692850B2 (en) * 2001-03-07 2004-02-17 Axsun Technologies, Inc. Controlled stress optical coatings for membranes
EP1387821A2 (en) 2001-05-10 2004-02-11 Merck & Co., Inc. Estrogen receptor modulators
EP1458400A1 (en) 2001-12-13 2004-09-22 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
CA2469779C (en) 2001-12-21 2008-02-12 The Procter & Gamble Company Method for the treatment of bone disorders
US20050070504A1 (en) 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
JP2005531532A (ja) 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
WO2003095029A1 (en) † 2002-05-10 2003-11-20 F. Hoffmann-La Roche Ag Bisphosphonic acid for the treatment and prevention of osteoporosis

Also Published As

Publication number Publication date
SI1596870T2 (sl) 2011-07-29
NZ536273A (en) 2007-08-31
KR100694550B1 (ko) 2007-03-13
EP1596870A1 (en) 2005-11-23
HRP20041013B1 (hr) 2013-10-25
CR7549A (es) 2006-02-07
AU2003250218A1 (en) 2004-07-14
PA8580601A1 (es) 2004-09-16
JO2663B1 (en) 2012-06-17
ZA200408822B (en) 2006-01-25
RU2004132186A (ru) 2006-01-27
CY1116123T1 (el) 2017-02-08
EP1596870B1 (en) 2007-08-08
RU2315603C2 (ru) 2008-01-27
DK1596870T3 (da) 2007-10-15
HK1080714A1 (en) 2006-05-04
TW200412978A (en) 2004-08-01
AR059723A2 (es) 2008-04-23
HRP20041013A2 (en) 2005-06-30
JP2006511560A (ja) 2006-04-06
AU2003250218B2 (en) 2006-10-26
US20040121007A1 (en) 2004-06-24
DE60315514T2 (de) 2008-04-24
AR037560A1 (es) 2004-11-17
JP4427453B2 (ja) 2010-03-10
CY1107757T1 (el) 2013-06-19
ES2291749T3 (es) 2008-03-01
CN1649598A (zh) 2005-08-03
CA2484494C (en) 2009-05-12
PT1790347E (pt) 2015-02-05
IL200849A0 (en) 2010-05-17
TWI342215B (en) 2011-05-21
ATE369139T1 (de) 2007-08-15
PE20040416A1 (es) 2004-07-12
EP1790347B1 (en) 2014-12-24
ES2530791T3 (es) 2015-03-05
IL164956A (en) 2013-02-28
SI1596870T1 (sl) 2007-12-31
CN1649598B (zh) 2011-12-07
NO20044722L (no) 2004-11-01
EG26027A (en) 2012-12-11
DK1596870T4 (da) 2011-06-14
DE60315514T3 (de) 2012-04-26
KR20050044762A (ko) 2005-05-12
ECSP045418A (es) 2005-01-03
MY143550A (en) 2011-05-31
US7923028B2 (en) 2011-04-12
EP1596870B2 (en) 2011-04-06
EP1790347A1 (en) 2007-05-30
CA2484494A1 (en) 2004-07-08
NO329690B1 (no) 2010-11-29
PL212072B1 (pl) 2012-08-31
MXPA04010866A (es) 2005-01-25
NZ555514A (en) 2008-12-24
DE60315514D1 (de) 2007-09-20
SI1790347T1 (sl) 2015-03-31
ES2291749T5 (es) 2011-07-21
UY27942A1 (es) 2004-02-27
BR0309691A (pt) 2005-08-02
IL164956A0 (en) 2005-12-18
WO2004056373A1 (en) 2004-07-08
DK1790347T3 (en) 2015-01-19
PT1596870E (pt) 2007-10-15
SG174628A1 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
HK1080714A1 (en) High dose ibandronate formulation
GB2389530B (en) Pharmaceutical compositions
GB0210397D0 (en) Pharmaceutical formulations
GB2391473B (en) Pharmaceutical compositions
TWI319317B (en) Modified release pharmaceutical formulation
GB0207438D0 (en) Formulation
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
AU2003226487A8 (en) Formulation
GB2392093B (en) Pharmaceutical formulations
GB0316206D0 (en) Pharmaceutical formulation
GB2392618B (en) Compositions for therapeutic use
GB0229258D0 (en) Medicinal compositions
IL149377A0 (en) Pharmaceutical formulation comprising melatonin
GB0222945D0 (en) Therapeutic compositions
GB0213481D0 (en) Pharmaceutical compositions
AU2003282722A8 (en) Therapeutic compositions
PL370907A1 (pl) Kompozycje farmaceutyczne
AU2003238900A8 (en) Pharmaceutical formulation
GB0310881D0 (en) Pharmaceutical formulation
GB0225041D0 (en) Pharmaceutical formulation
GB0225040D0 (en) Formulation
GB0215591D0 (en) Formulation
GB0215589D0 (en) Formulation
GB0217078D0 (en) Formulation
GB0209379D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
RECP Rectifications of patent specification